CN113018518B - 一种用于婴幼儿狭窄血管可吸收血管支架涂层的制备方法 - Google Patents
一种用于婴幼儿狭窄血管可吸收血管支架涂层的制备方法 Download PDFInfo
- Publication number
- CN113018518B CN113018518B CN202110246916.5A CN202110246916A CN113018518B CN 113018518 B CN113018518 B CN 113018518B CN 202110246916 A CN202110246916 A CN 202110246916A CN 113018518 B CN113018518 B CN 113018518B
- Authority
- CN
- China
- Prior art keywords
- drug
- coating
- absorbable
- stent
- spraying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000576 coating method Methods 0.000 title claims abstract description 95
- 239000011248 coating agent Substances 0.000 title claims abstract description 93
- 230000002792 vascular Effects 0.000 title claims abstract description 75
- 210000004204 blood vessel Anatomy 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 139
- 229940079593 drug Drugs 0.000 claims abstract description 132
- 238000005507 spraying Methods 0.000 claims abstract description 120
- 239000000693 micelle Substances 0.000 claims abstract description 96
- 239000000243 solution Substances 0.000 claims abstract description 92
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 55
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims abstract description 31
- 229920001577 copolymer Polymers 0.000 claims abstract description 30
- 239000007864 aqueous solution Substances 0.000 claims abstract description 23
- 238000003756 stirring Methods 0.000 claims abstract description 21
- 238000001704 evaporation Methods 0.000 claims abstract description 13
- 229920000469 amphiphilic block copolymer Polymers 0.000 claims abstract description 10
- 238000001914 filtration Methods 0.000 claims abstract description 10
- 239000000622 polydioxanone Substances 0.000 claims abstract description 9
- 238000000502 dialysis Methods 0.000 claims abstract description 8
- 238000000926 separation method Methods 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 229920000642 polymer Polymers 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 53
- 230000008569 process Effects 0.000 claims description 44
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 37
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 30
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 30
- 229960002930 sirolimus Drugs 0.000 claims description 30
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 26
- 229960001680 ibuprofen Drugs 0.000 claims description 26
- 238000000520 microinjection Methods 0.000 claims description 24
- 238000005406 washing Methods 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000012535 impurity Substances 0.000 claims description 10
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 10
- 239000012498 ultrapure water Substances 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000011247 coating layer Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 8
- 230000008020 evaporation Effects 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 230000002966 stenotic effect Effects 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 210000000663 muscle cell Anatomy 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000010410 layer Substances 0.000 claims description 3
- 239000012982 microporous membrane Substances 0.000 claims description 2
- 229910001873 dinitrogen Inorganic materials 0.000 claims 3
- 230000015556 catabolic process Effects 0.000 abstract description 13
- 238000006731 degradation reaction Methods 0.000 abstract description 13
- 230000004044 response Effects 0.000 abstract description 3
- 229920001661 Chitosan Polymers 0.000 description 9
- 239000000463 material Substances 0.000 description 7
- 239000004005 microsphere Substances 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920001610 polycaprolactone Polymers 0.000 description 4
- 239000004632 polycaprolactone Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 2
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009954 braiding Methods 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000009998 heat setting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002074 melt spinning Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000005077 saccule Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/02—Processes for applying liquids or other fluent materials performed by spraying
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D3/00—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials
- B05D3/10—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by other chemical means
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D7/00—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials
- B05D7/24—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials for applying particular liquids or other fluent materials
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D7/00—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials
- B05D7/50—Multilayers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/626—Liposomes, micelles, vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/06—Coatings containing a mixture of two or more compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
本发明提供了一种用于婴幼儿狭窄血管的可吸收血管支架涂层的载药胶束的制备方法,包括以下步骤:S1:将待包封药物溶解在适量乳化剂中,然后加入壳聚糖‑聚对二氧环己酮两亲性嵌段共聚物充分混匀配成药物‑共聚物溶液;S2:将S1所得的药物‑共聚物溶液逐滴至预先配制好的乳化剂水溶液中,并持续搅直到形成稳定的载药胶束溶液;S3:将S2所述胶束溶液经减压蒸发去除乳化剂后再搅拌,产物依次经离心分离、过滤、透析,即得载药胶束;并具体公开了将载药胶束喷涂在可吸收血管支架表面制备载药涂层,显著提高了其生物相容性,并达到了pH响应型载药胶束随支架骨架及空白顶层降解的pH值变化而达到缓释药物的目的。
Description
技术领域
本发明涉及医药技术领域,具体涉及一种用于婴幼儿狭窄血管可吸收血管支架涂层的制备方法。
背景技术
经皮植入血管支架相较于人工血管置换及单纯球囊扩张血管具有创伤性小、疗效佳的优势。多数专家学者都认为可吸收支架在儿童血管狭窄性病变中的应用具有较高的临床研究价值,且其能够克服永久性金属支架植入后小儿在长大以后支架段血管相对狭窄、需反复扩张及致栓性等诸多严重问题,而这些问题治疗难度极高。目前可吸收支架研究在国内外已广泛开展,而针对婴幼儿血管狭窄性疾病设计的可吸收支架尚缺乏。
应用于生物可吸收支架的材料多为高分子多聚物,包括聚左旋乳酸(poly L-lactic acid,PLLA),聚乙交酯(Polyglycolide,PGA),聚乙丙交酯(poly lactic-glycolicacid,PLGA),聚对二氧环己酮(Poly[para-dioxanone],PPDO),聚己内酯(PCL)等,这些材料具有不同的降解时间,制作成血管支架时具有不同的机械强度以适应不同的血管支撑要求,降解产物安全无毒性可以随细胞代谢排出体外。制备方法上,多是先把可降解聚合物通过熔融纺丝或溶液铸膜切割成支架基材纤维,再在模具上缠绕成设计的支架形状,加热固化成型。
综合国内外研究分析,多聚物可吸收支架多适用于成年人冠状动脉等小血管直径(血管直径3-5mm),降解周期较长多为2-3年,制备方法复杂生产成本高;且可吸收支架径向支撑性能要低于传统的金属支架,不能适应于儿童使用。例如,现有技术(CN108066048B)公开了:制备热粘合复合结构可降解管腔支架,通过制备热粘合PPDO/PCL皮芯结构编织纱并将其与PPDO单丝交叉编织组成支架预成型体,热黏合编织纱限制了编织结构中部分交织点的滑移和转动从而提高支架的机械性能,再经过热定型处理,得到结构稳定的PPDO/PCL编织自增强型血管支架。这种支架在体内4月内能维持较好的血管支撑作用,12月大部分支架杆完全降解与血管壁融合,支架降解适配儿童血管生长发育需求。然而,支架降解中期(4-6月)生物相容性欠佳,支架炎症反应及平滑肌细胞增殖被认为是聚合物支架管腔再狭窄的主要因素,会诱发血栓形成及不良血管事件,引起支架疗效欠佳。故提供初始体积小(长度和直径符合要求)、支架的支撑力至少需要维持3~6个月以完成血管修复,支架完全降解时间在6-12月以适应儿童血管发育速率以及具有良好的生物相容性的血管支架是本领域亟待解决的问题。
发明内容
为克服现有技术中的缺陷,本发明设计并构建适用于婴幼儿狭窄血管的可吸收血管支架的载药复合涂层,以调控可吸收血管支架生物相容性:提供了一种新的药物释放途径,可在支架降解早期不影响受损血管的再内皮化,在降解中期释放药物发挥抗炎、抗增殖作用;涂层材料在释放药物后能生物降解,不增加晚期血栓形成的发生率,最终达到支架整体完全可生物降解的技术效果。
本发明通过如下技术方案实现:
本发明的第一方面提供了一种用于婴幼儿狭窄血管的可吸收血管支架涂层的聚合物载药胶束溶液的制备方法,包括以下步骤:
S1:将待包封药物溶解在适量乳化剂中,然后加入壳聚糖-聚对二氧环己酮两亲性嵌段共聚物(即Chitosan-b-PPDO共聚物)充分混匀配成药物-共聚物溶液,其中,所述待包封药物与Chitosan-b-PPDO共聚物的质量比10:20~60;优选的,所述,所述待包封药物与Chitosan-b-PPDO共聚物的质量比10:25;
S2:将S1所得的药物-共聚物溶液逐滴至预先配制好的乳化剂水溶液中,并持续搅拌12~36h,直到形成稳定的载药胶束溶液,其中,所述乳化剂水溶液中乳化剂:水的质量比为1:0.5~2,且所述药物-共聚物溶液占所述乳化剂水溶液质量的2~10%;优选的,所述持续搅拌时间为24h;优选的,所述药物-共聚物溶液占所述乳化剂水溶液质量的3.5%;优选的,所述乳化剂水溶液中乳化剂:水的质量比为1:1;
S3:将S2所得载药胶束溶液经减压蒸发去除乳化剂后再搅拌2~4小时,产物依次经离心分离获得上清液、上清液再经过滤获得滤液、滤液再经过透析,以至完全除去未包封的共聚物以及残留的乳化剂,即得所述聚合物载药胶束溶液;优选的,所述搅拌时间为3h;
本发明的第二方面提供了一种用于婴幼儿狭窄血管的可吸收血管支架涂层聚合物空白胶束溶液的制备方法,包括以下步骤:
S1’:将Chitosan-b-PPDO共聚物溶解在少量乳化剂中配成共聚物溶液,然后逐滴滴至预先配制好的乳化剂水溶液中,并持续搅拌12~36h,直到形成稳定的胶束溶液,其中,所述乳化剂水溶液中乳化剂:水的质量比为1:0.5~2,且所述共聚物溶液占所述乳化剂水溶液质量的2~10%;优选的,所述持续搅拌时间为24h;优选的,共聚物溶液占所述乳化剂水溶液质量的3.5%;优选的,所述乳化剂水溶液中乳化剂:水的质量比为1:1;
S2’:将S2所得载药胶束溶液经减压蒸发去除乳化剂后再搅拌2~4小时,产物依次经离心分离获得上清液、上清液再经过滤获得滤液、滤液再经过透析,以至完全除去未包封的共聚物以及残留的乳化剂,即得所述聚合物载药胶束溶液;优选的,所述搅拌时间为3h;
进一步的,S1中,所述药物为抗平滑肌细胞增殖药物和/或抗炎药物;
更进一步的,所述抗平滑肌细胞增殖药物为雷帕霉素;
更进一步的,所述抗炎药物为布洛芬;
进一步的,S1和S1’中,所述壳聚糖-聚对二氧环己酮两亲性嵌段共聚物(即Chitosan-b-PPDO共聚物)如式Ⅰ所示,
其中,R为H或OCH3;n1和n2均为正整数且n1:n2为1:10~20;
更进一步的,所述壳聚糖-b-聚对二氧环己酮(PPDO)两亲性嵌段共聚物的制备方法包括如下步骤:
其中,R为H或OCH3,n1和n2均为正整数且n1:n2为1:10~20;
进一步的,上述步骤中,所述乳化剂为丙酮、二氯甲烷或氯仿:
进一步的,S3和S2’中,所述减压蒸发的温度为160~170℃,且压力为1~3mmHg;优选的,S3和S2’中,所述减压蒸发的温度为165℃,且压力为2mmHg;
进一步的,S3和S2’中,所述过滤为采用微孔滤膜过滤;
进一步的,S3和S2’中,所述透析条件为采用截留分子量≥3500透析袋;
本发明的第三方面还提供了一种用于婴幼儿狭窄血管的可吸收血管支架涂层的聚合物载药胶束溶液,采用上述任一项制备聚合物载药胶束溶液的方法获得;
本发明的第四方面还提供了一种用于婴幼儿狭窄血管的可吸收血管支架涂层的聚合物空白胶束溶液,采用上述任一项制备聚合物空白胶束溶液的方法获得;
本发明的第五方面还提供了一种上述用于婴幼儿狭窄血管可吸收血管支架涂层载药胶束的喷涂方法,包括以下步骤:
S1制备载药涂层:以上述聚合物载药胶束溶液为喷涂液,采用超声喷涂工艺将其均匀喷涂在可吸收血管支架表面获得含药物涂层的可吸收血管支架;进一步的,所述药物涂层包括雷帕霉素药物涂层和/或布洛芬药物涂层;进一步优选的,所述药物涂层包括雷帕霉素药物涂层和布洛芬药物涂层,且雷帕霉素药物涂层:布洛芬药物涂层数之比为4:3;
S2制备空白涂层:以上述聚合物空白胶束溶液为喷涂液,采用超声喷涂工艺将其均匀喷涂在所述含药物涂层的可吸收血管支架表面,以获得含空白涂层的可吸收血管支架,其中,所述含药物涂层:空白涂层数之比为7:3;
进一步的,S1所述超声喷涂工艺包括:
S11:将可吸收血管支架经酸洗清除支架表面杂质、超纯水冲洗以去除其表面的酸,真空干燥后固定于自动超声喷涂仪上;
S12:将聚合物载药胶束溶液装夹到微量注射泵上,采用超声喷涂工艺将其均匀喷涂在可吸收血管支架表面获得含药物涂层的可吸收血管支架,其中,所述超声喷涂工艺中,超声功率为2~5W,优选3.5W;微量注射泵流量为3~5mL/h,优选4mL/h;氮气气压为2~5psi,优选3.5psi;转动心轴的旋转速度100~300rpm,优选200rpm;
更进一步的,S12步骤包括:
A.制备含雷帕霉素的药物涂层:以雷帕霉素聚合物载药胶束溶液为喷涂液,采用超声喷涂工艺将其均匀喷涂在可吸收血管支架表面,获得含雷帕霉素药物涂层的可吸收血管支架,其中,所述超声喷涂工艺中,超声功率为2~5W,优选3.5W;微量注射泵流量为3~5mL/h,优选4mL/h;氮气气压为2~5psi,优选3.5psi;转动心轴的旋转速度100~300rpm,优选200rpm;
或B.制备含布洛芬的药物涂层:以布洛芬聚合物载药胶束为喷涂液,采用超声喷涂工艺将其均匀喷涂在可吸收血管支架表面获得含布洛芬药物涂层的可吸收血管支架,其中,所述超声喷涂工艺中,超声功率为2~5W,优选3.5W;微量注射泵流量为3~5mL/h,优选4mL/h;氮气气压为2~5psi,优选3.5psi;转动心轴的旋转速度100~300rpm,优选200rpm;
或C.制备含雷帕霉素和布洛芬的混合药物涂层:以雷帕霉素聚合物载药胶束溶液为喷涂液,采用超声喷涂工艺将其均匀喷涂在所述可吸收血管支架表面;然后再以布洛芬聚合物载药胶束溶液为喷涂液,采用超声喷涂工艺将其均匀喷涂在上述制备的含雷帕霉素药物涂层的可吸收血管支架表面,获得含混合载药涂层的可吸收血管支架,且雷帕霉素药物涂层:布洛芬药物涂层数之比为4:3,其中,所述超声喷涂工艺中,超声功率为2~5W,优选3.5W;微量注射泵流量为3~5mL/h,优选4mL/h;氮气气压为2~5psi,优选3.5psi;转动心轴的旋转速度100~300rpm,优选200rpm;
进一步的,S2所述超声喷涂工艺包括:
S21:将可吸收血管支架经酸洗清除支架表面杂质、超纯水冲洗以去除其表面的酸,然后真空干燥后固定于自动超声喷涂仪上;
S22:以上述聚合物空白胶束溶液为喷涂液,采用超声喷涂工艺将其均匀喷涂在所述含药物涂层表面的可吸收血管支架上,获得含空白层的可吸收血管支架,其中,所述含药物涂层:空白涂层数之比为7:3;所述超声喷涂工艺中,超声功率为2~5W,优选3.5W;微量注射泵流量为3~5mL/h,优选4mL/h;氮气气压为2~5psi,优选3.5psi;转动心轴的旋转速度100~300rpm,优选200rpm。
附图说明
图1:本发明反应的反应式
图2:本发明的制备可吸收血管支架的流程示意图
有益效果
本发明制备的载药胶束涂层,喷涂在可降解吸收生物支架表面,具有以下优势:(1)在支架降解早期不影响受损血管的再内皮化,在降解中期释放药物发挥抗炎、抗增殖作用,涂层材料在释放药物后能生物降解,不增加晚期血栓形成的发生率,最终达到支架整体完全可生物降解,显著提高了可吸收支架的生物相容性;(2)以复合涂层方式,先喷涂载药胶束,再喷涂不载药的空白胶束,使得pH响应型载药胶束随支架骨架及空白顶层降解的pH值变化而达到缓释药物的目的。
具体实施方式
下面结合附图和具体实施方式对本发明作进一步详细的说明。
在一个具体的实施方式中,本发明使用的支架来自CN108066048B公开的制备方法制备的可吸收血管支架。
实施例1:pH响应型Chitosan-b-PPDO聚合物的合成
将对二氧环己酮(PDO)单体加入辛酸亚锡催化剂(SnOct2:PDO摩尔量之比为1:10000)并置入反应器中,然后用液氮冷冻,再将反应器置于80℃下的油浴中反应48h,然后将反应器冷却到0℃,使反应停止,获得羟基封端PPDO单体(OH-PPDO-BA);将OH-PPDO-BA溶于的丙烯酰氯中(OH-PPDO-BA:丙烯酰氯摩尔量之比为1:8),然后再加入与OH-PPDO-BA等摩尔量的三乙胺(TEA)作为催化剂,避光25℃下反应进行10小时,然后加入乙醚除去未反应的试剂,用去离子水洗涤三次,除去反应过程中形成的不溶性物,在真空40℃下干燥12h,获得端烯丙基PPDO(allyl-PPDO-BA);将摩尔量15份壳聚糖(Mn=8*105,脱乙酰度100%)溶于0.1mol/L醋酸水溶液中,在惰性气体保护下,再添加K2SO8(KPS),25℃下混合搅拌20分钟,摩尔量85份allyl-PPDO-BA随后加入,在50℃下共聚2小时,丙酮和去离子水清洗除去未反应的均聚物,冷却后即得Chitosan-b-PPDO共聚物(分子量Mn=3100g/mol)。共聚位点定位在壳聚糖的自由基上,同时保留了壳聚糖主链上的游离氨基。支架在降解中期,PPDO链中间的降解产物堆积,导致了支架杆周局部pH值降低的“酸性”微环境,而由于壳聚糖带有氨基基团,其酸碱解离度pKa在6.3-7.0(20℃),正好处于血液(pH值7.4)和PPDO降解酸性微环境(pH值6.0-7.0)之间,故使得壳聚糖氨基质子化,进而胶束结构变化膨胀,以促进疏水端包裹药物的释放,从而实现pH响应型胶束的功能。
嵌段位点在壳聚糖的自由基上,同时保留了壳聚糖主链上的游离氨基,从而实现pH敏感性。一般来说,两亲性共聚物中疏水基团含量和共聚物分子量将会大大影响其自组装纳米胶束的粒径大小。实验通过控制PPDO微球分子量,制得Polymer1(Chitosan-b-PPDO940(Mn=3100))和Polymer2(Chitosan-b-PPDO2000(Mn=6200))。
实施例2:聚合物载药胶束的制备
S1:将待包封药物(布洛芬/10毫克或雷帕霉素/10毫克)溶解在3.5mL溶剂(无水氯仿或丙酮、二氯甲烷)中,然后加入25mg实施例1合成的Chitosan-b-PPDO(分别加Polymer1和Polymer2)充分混匀溶解配成药物-共聚物溶液;
S2:将S1所得的药物-共聚物溶液逐滴滴至预先配制好的乳化剂水溶液中,并持续搅拌24h,直到形成稳定的载药胶束溶液,其中,所述乳化剂水溶液中乳化剂:水的质量比为1:1,且所述药物-共聚物溶液占所述乳化剂水溶液质量的3.5%;
S3:将所得载药胶束溶液经减压蒸发去除乳化剂后再搅拌3小时,产物经离心分离、0.22μm滤膜过滤以及截留分子量为3500的透析膜透析,除去未绑定的共聚物、残留的乳化剂和溶剂,即制备成聚合物载药胶束溶液。
实施例3:空白胶束的制备
S1:将Chitosan-b-PPDO共聚物溶解在少量乳化剂中配成溶液,然后逐滴滴至预先配制好的乳化剂水溶液中,并持续搅拌24h,直到形成稳定的载药胶束溶液,所述乳化剂水溶液中乳化剂:水的质量比为1:1,且所述药物-共聚物溶液占所述乳化剂水溶液质量的3.5%;
S2:将所得载药胶束溶液经减压蒸发去除乳化剂后再搅拌3小时,产物经离心分离、0.22μm滤膜过滤以及截留分子量为3500的透析膜透析,除去未绑定的共聚物、残留的乳化剂和溶剂,即制备成聚合物空白胶束溶液。
采用动态光散射(DLS)测定载药胶束粒径(D)和分布(分散系数PDI),高效液相色谱(HPLC)法测定这几种胶束载药率(LC%)、包封率(EE%),结果如表1所示。与未包裹雷帕霉素的聚合物微球相比,包裹药物后聚合物微球的粒径明显增大,可以说明雷帕霉素被包裹在了其中。同时我们看到Polymer1-空白微球粒径稍大于Polymer2-空白微球,其原因是短PPDO链的结晶性能较差,胶束的芯部较松散,胶束体积增大;但载药后两者差异不显著均约170nm。两种载药微球的载药率及包封率均较低。
表1 Chitosan-b-PPDO共聚物表征检测结果
实施例4:具有载药(雷帕霉素)涂层的支架制备工艺
一种用于婴幼儿狭窄血管可吸收血管支架涂层载药胶束的喷涂方法,包括以下步骤:
S1载药涂层:S11:将可吸收血管支架经酸洗清除支架表面杂质、超纯水冲洗以去除其表面的酸,然后真空干燥后固定于自动超声喷涂仪上;S12:以雷帕霉素聚合物载药胶束溶液为喷涂液,采用超声喷涂工艺将其均匀喷涂在所述可吸收血管支架表面,共喷涂7次,获得含药物涂层的可吸收血管支架,其中,所述超声喷涂工艺中,超声功率为3.5W;微量注射泵流量为4mL/h;氮气气压为3.5psi;转动心轴的旋转速为200rpm;
S2制备空白涂层:S21:采用酸洗清上述S1制备的含载药涂层支架,以去除支架表面杂质,然后以超纯水冲洗以去除其表面的酸,然后真空干燥后将其固定于自动超声喷涂仪上;S22:将聚合物空白胶束溶液装夹到微量注射泵上,采用超声喷涂工艺将其均匀喷涂在上述S21制备的含药物涂层可吸收血管支架表面获得空白涂层,共喷涂3次,其中,所述超声喷涂工艺中,超声功率为3.5W;微量注射泵流量为4mL/h;氮气气压为3.5psi;转动心轴的旋转速为200rpm。
实施例5:具有载药(布洛芬)涂层的支架制备工艺
一种用于婴幼儿狭窄血管可吸收血管支架涂层载药胶束的喷涂方法,包括以下步骤:
S1载药涂层:S11:将可吸收血管支架经酸洗清除支架表面杂质、超纯水冲洗以去除其表面的酸,然后真空干燥后固定于自动超声喷涂仪上;S12:以布洛芬聚合物载药胶束溶液为喷涂液,采用超声喷涂工艺将其均匀喷涂在所述可吸收血管支架表面,共喷涂7次,获得含药物涂层的可吸收血管支架,其中,所述超声喷涂工艺中,超声功率为3.5W;微量注射泵流量为4mL/h;氮气气压为3.5psi;转动心轴的旋转速为200rpm;
S2制备空白涂层:S21:采用酸洗清上述S1制备的含载药涂层支架,以去除支架表面杂质,然后以超纯水冲洗以去除其表面的酸,然后真空干燥后将其固定于自动超声喷涂仪上;S22:将聚合物空白胶束溶液装夹到微量注射泵上,采用超声喷涂工艺将其均匀喷涂在上述S21制备的含药物涂层可吸收血管支架表面获得空白涂层,共喷涂3次,其中,所述超声喷涂工艺中,超声功率为3.5W;微量注射泵流量为4mL/h;氮气气压为3.5psi;转动心轴的旋转速为200rpm。
实施例6:具有混合载药(雷帕霉素和布洛芬)涂层的支架制备工艺
一种用于婴幼儿狭窄血管可吸收血管支架涂层载药胶束的喷涂方法,包括以下步骤:
S1制备载药涂层:S11:将可吸收血管支架经酸洗清除支架表面杂质、超纯水冲洗以去除其表面的酸,然后真空干燥后固定于自动超声喷涂仪上;S12:以雷帕霉素聚合物载药胶束溶液为喷涂液,采用超声喷涂工艺将其均匀喷涂在所述可吸收血管支架表面,共喷涂4次;S13:再以布洛芬聚合物载药胶束溶液为喷涂液,采用超声喷涂工艺将其均匀喷涂在S12制备的所述可吸收血管支架表面,共喷涂3次,获得含混合载药涂层的可吸收血管支架;其中,所述超声喷涂工艺中,超声功率为3.5W;微量注射泵流量为4mL/h;氮气气压为3.5psi;转动心轴的旋转速为200rpm;
S2制备空白涂层:S21:采用酸洗清上述S1制备的含载药涂层支架,以去除支架表面杂质,然后以超纯水冲洗以去除其表面的酸,然后真空干燥后将其固定于自动超声喷涂仪上;S22:将聚合物空白胶束溶液装夹到微量注射泵上,采用超声喷涂工艺将其均匀喷涂在上述S21制备的含药物涂层可吸收血管支架表面获得空白涂层,共喷涂3次,其中,所述超声喷涂工艺中,超声功率为3.5W;微量注射泵流量为4mL/h;氮气气压为3.5psi;转动心轴的旋转速为200rpm。
以上详细描述了本发明的较佳具体实施例。应当理解,本领域的普通技术人员无需创造性劳动就可以根据本发明的构思做出诸多修改和变化。因此,凡本技术领域中技术人员依本发明的构思在现有技术的基础上通过逻辑分析、推理或者有限的实验可以得到的技术方案,皆应在由权利要求书所确定的保护范围内。
Claims (28)
1.一种用于制备婴幼儿狭窄血管可吸收血管支架涂层胶束的喷涂方法,其特征在于,包括以下步骤:
S1制备载药涂层:以婴幼儿狭窄血管可吸收血管支架涂层的聚合物载药胶束溶液为喷涂液,采用超声喷涂工艺将其均匀喷涂在可吸收血管支架表面获得含药物涂层的可吸收血管支架;
S2制备空白涂层:以聚合物空白胶束溶液为喷涂液,采用超声喷涂工艺将其均匀喷涂在含上述药物涂层的可吸收血管支架表面,以获得含空白涂层的可吸收血管支架,其中,所述含药物涂层:空白涂层数之比为7:3;
其中,所述婴幼儿狭窄血管可吸收血管支架涂层的聚合物载药胶束溶液的制备方法,包括以下步骤:
S1:将待包封药物溶解在适量乳化剂中,然后加入壳聚糖-聚对二氧环己酮两亲性嵌段共聚物充分混匀配成药物-共聚物溶液,其中,所述待包封药物与壳聚糖-聚对二氧环己酮两亲性嵌段共聚物的质量比10:20~60;所述药物为抗平滑肌细胞增殖药物和/或抗炎药物;所述抗平滑肌细胞增殖药物为雷帕霉素;所述抗炎药物为布洛芬;
S2:将S1所得的药物-共聚物溶液逐滴至预先配制好的乳化剂水溶液中,并持续搅拌12~36h,直到形成稳定的载药胶束溶液,其中,所述乳化剂水溶液中乳化剂:水的质量比为1:0.5~2,且所述药物-共聚物溶液占所述乳化剂水溶液质量的2~10%;
S3:将S2所述胶束溶液经减压蒸发去除乳化剂后再搅拌2~4小时,产物依次经离心分离获得上清液、上清液再经过滤获得滤液、滤液再经过透析,以至完全除去未包封的共聚物以及残留的乳化剂,即得所述聚合物载药胶束溶液;
其中,所述婴幼儿狭窄血管可吸收血管支架涂层的聚合物空白胶束溶液的制备方法,其特征在于,包括以下步骤:
S1’:将壳聚糖-聚对二氧环己酮两亲性嵌段共聚物溶解在少量乳化剂中配成共聚物溶液,然后逐滴滴至预先配制好的乳化剂水溶液中,并持续搅拌12~36h,直到形成稳定的胶束溶液,其中,所述乳化剂水溶液中乳化剂:水的质量比为1:0.5~2,且所述共聚物溶液占所述乳化剂水溶液质量的2~10%;
S2’:将S1所述胶束溶液经减压蒸发去除乳化剂后再搅拌2~4小时,产物依次经离心分离获得上清液,上清液再经过滤获得滤液,滤液再经过透析,以至完全除去未绑定的共聚物和残留的乳化剂,即得;
其中,所述乳化剂为无水氯仿、丙酮或二氯甲烷。
2.根据权利要求1所述的用于制备婴幼儿狭窄血管可吸收血管支架涂层胶束的喷涂方法,其特征在于,所述待包封药物与壳聚糖-聚对二氧环己酮两亲性嵌段共聚物的质量比10:25。
3.根据权利要求1所述的用于制备婴幼儿狭窄血管可吸收血管支架涂层胶束的喷涂方法,其特征在于,所述持续搅拌时间为24h。
4.根据权利要求1所述的用于制备婴幼儿狭窄血管可吸收血管支架涂层胶束的喷涂方法,其特征在于,所述药物-共聚物溶液占所述乳化剂水溶液质量的3.5%。
5.根据权利要求1所述的用于制备婴幼儿狭窄血管可吸收血管支架涂层胶束的喷涂方法,其特征在于,所述乳化剂水溶液中乳化剂:水的质量比为1:1。
6.根据权利要求1所述的用于制备婴幼儿狭窄血管可吸收血管支架涂层胶束的喷涂方法,所述搅拌时间为3h。
9.根据权利要求1所述的用于制备婴幼儿狭窄血管可吸收血管支架涂层胶束的喷涂方法,其特征在于,S3和S2’中,所述减压蒸发的温度为160~170℃,且所述减压蒸发的压力为1~3mmHg。
10.根据权利要求9所述的用于制备婴幼儿狭窄血管可吸收血管支架涂层胶束的喷涂方法,其特征在于,S3和S2’中,所述减压蒸发的温度为165℃,且所述减压蒸发的压力为2mmHg。
11.根据权利要求1所述的用于制备婴幼儿狭窄血管可吸收血管支架涂层胶束的喷涂方法,其特征在于,S3和S2’中,所述过滤为采用微孔滤膜过滤。
12.根据权利要求1所述的用于制备婴幼儿狭窄血管可吸收血管支架涂层胶束的喷涂方法,其特征在于,S3和S2’中,所述透析条件为采用截留分子量≥3500透析袋。
13.根据权利要求1所述的用于制备婴幼儿狭窄血管可吸收血管支架涂层胶束的喷涂方法,其特征在于,所述药物涂层为雷帕霉素药物涂层和布洛芬药物涂层,且所述雷帕霉素药物涂层:布洛芬药物涂层数之比为4:3。
14.根据权利要求1~13任一项所述的喷涂方法,其特征在于,S1所述超声喷涂工艺包括:
S11:将可吸收血管支架经酸洗清除支架表面杂质、超纯水冲洗以去除其表面的酸,真空干燥后固定于自动超声喷涂仪上;
S12:将聚合物载药胶束溶液装夹到微量注射泵上,采用超声喷涂工艺将其均匀喷涂在可吸收血管支架表面获得含药物涂层的可吸收血管支架,其中,所述超声喷涂工艺中,超声功率为2~5W;微量注射泵流量为3~5mL/h;氮气气压为2~5psi;转动心轴的旋转速度100~300rpm。
15.根据权利要求14所述的喷涂方法,其特征在于,所述超声功率为3.5W。
16.根据权利要求14所述的喷涂方法,其特征在于,所述转动心轴的旋转速度200rpm。
17.根据权利要求14所述的喷涂方法,其特征在于,所述氮气气压为3.5psi。
18.根据权利要求14所述的喷涂方法,其特征在于,所述微量注射泵流量为4mL/h。
19.根据权利要求14所述的喷涂方法,其特征在于,S12步骤包括:
A.制备含雷帕霉素的药物涂层:以雷帕霉素聚合物载药胶束溶液为喷涂液,采用超声喷涂工艺将其均匀喷涂在可吸收血管支架表面,获得含雷帕霉素药物涂层的可吸收血管支架,其中,所述超声喷涂工艺中,超声功率为2~5W;微量注射泵流量为3~5mL/h;氮气气压为2~5psi;转动心轴的旋转速度100~300rpm;
或B.制备含布洛芬的药物涂层:以布洛芬聚合物载药胶束为喷涂液,采用超声喷涂工艺将其均匀喷涂在可吸收血管支架表面获得含布洛芬药物涂层的可吸收血管支架,其中,所述超声喷涂工艺中,超声功率为2~5W;微量注射泵流量为3~5mL/h;氮气气压为2~5psi;转动心轴的旋转速度100~300rpm;
或C.制备含雷帕霉素和布洛芬的混合药物涂层:以雷帕霉素聚合物载药胶束溶液为喷涂液,采用超声喷涂工艺将其均匀喷涂在所述可吸收血管支架表面;然后再以布洛芬聚合物载药胶束溶液为喷涂液,采用超声喷涂工艺将其均匀喷涂在上述制备的含雷帕霉素药物涂层的可吸收血管支架表面,且雷帕霉素药物涂层:布洛芬药物涂层数之比为4:3,获得含混合载药涂层的可吸收血管支架,其中,所述超声喷涂工艺中,超声功率为2~5W;微量注射泵流量为3~5mL/h;氮气气压为2~5psi;转动心轴的旋转速度100~300rpm。
20.根据权利要求19所述的喷涂方法,其特征在于,所述超声功率为3.5W。
21.根据权利要求19所述的喷涂方法,其特征在于,所述微量注射泵流量为4mL/h。
22.根据权利要求19所述的喷涂方法,其特征在于,所述氮气气压为3.5psi。
23.根据权利要求19所述的喷涂方法,其特征在于,所述转动心轴的旋转速度200rpm。
24.根据权利要求1~13任一项所述的喷涂方法,其特征在于,S2所述超声喷涂工艺包括:
S21:将可吸收血管支架经酸洗清除支架表面杂质、超纯水冲洗以去除其表面的酸,然后真空干燥后固定于自动超声喷涂仪上;
S22:以上述聚合物空白胶束溶液为喷涂液,采用超声喷涂工艺将其均匀喷涂在所述含药物涂层表面的可吸收血管支架上,获得含空白层的可吸收血管支架,其中,所述含药物涂层:空白涂层数之比为7:3;所述超声喷涂工艺中,超声功率为2~5W;微量注射泵流量为3~5mL/h;氮气气压为2~5psi;转动心轴的旋转速度100~300rpm。
25.根据权利要求24所述的喷涂方法,其特征在于,所述超声功率为3.5W。
26.根据权利要求24所述的喷涂方法,其特征在于,所述微量注射泵流量为4mL/h。
27.根据权利要求24所述的喷涂方法,其特征在于,所述氮气气压为3.5psi。
28.根据权利要求24所述的喷涂方法,其特征在于,所述转动心轴的旋转速度200rpm。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110246916.5A CN113018518B (zh) | 2021-03-05 | 2021-03-05 | 一种用于婴幼儿狭窄血管可吸收血管支架涂层的制备方法 |
PCT/CN2022/083531 WO2022184183A1 (zh) | 2021-03-05 | 2022-03-29 | 一种用于婴幼儿狭窄血管可吸收血管支架涂层的制备方法 |
US18/280,275 US11986575B2 (en) | 2021-03-05 | 2022-03-29 | Preparation method of absorbable vascular stent coating for angiostenosis in infant |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110246916.5A CN113018518B (zh) | 2021-03-05 | 2021-03-05 | 一种用于婴幼儿狭窄血管可吸收血管支架涂层的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113018518A CN113018518A (zh) | 2021-06-25 |
CN113018518B true CN113018518B (zh) | 2022-06-03 |
Family
ID=76468306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110246916.5A Active CN113018518B (zh) | 2021-03-05 | 2021-03-05 | 一种用于婴幼儿狭窄血管可吸收血管支架涂层的制备方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11986575B2 (zh) |
CN (1) | CN113018518B (zh) |
WO (1) | WO2022184183A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113018518B (zh) | 2021-03-05 | 2022-06-03 | 上海交通大学医学院附属新华医院 | 一种用于婴幼儿狭窄血管可吸收血管支架涂层的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN202069770U (zh) * | 2011-05-19 | 2011-12-14 | 中南大学 | 空白药物载体贴膜 |
CN112043878A (zh) * | 2020-08-06 | 2020-12-08 | 苏州大学 | 一种抗凝血管支架覆膜及其制备方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050208095A1 (en) * | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
GB0608345D0 (en) | 2006-04-27 | 2006-06-07 | Univ Warwick | Implant |
CN101703428B (zh) * | 2009-10-28 | 2012-05-09 | 西南交通大学 | 一种具有防再狭窄涂层的血管支架及其制备方法 |
CN102205151A (zh) * | 2011-05-23 | 2011-10-05 | 中国医学科学院生物医学工程研究所 | 固载抗菌药物疝补片及制备方法 |
CN103157132A (zh) | 2011-12-13 | 2013-06-19 | 西安瑞捷生物科技有限公司 | 一种人工小血管支架 |
EP2938367B1 (en) | 2012-12-28 | 2020-12-16 | Boston Scientific Scimed, Inc. | Methods, compositions and kits for surgical repair |
CN103920153A (zh) * | 2014-05-06 | 2014-07-16 | 中国科学院上海硅酸盐研究所 | 一种壳聚糖修饰的pH响应性载药缓控释材料及其制备方法 |
CN104225683B (zh) | 2014-07-09 | 2016-07-06 | 广州迈普再生医学科技有限公司 | 加载三七的止血组织修复膜及其制备方法 |
CN104559218B (zh) * | 2015-01-12 | 2017-06-16 | 山东理工大学 | 一种聚对二氧环己酮与羧甲基壳聚糖改进聚肽膜亲水性与柔顺性的方法 |
US10098964B2 (en) * | 2015-03-12 | 2018-10-16 | The Board Of Trustees Of The University Of Illinois | Inclusion complexes and methods for making the same |
US10632228B2 (en) | 2016-05-12 | 2020-04-28 | Acera Surgical, Inc. | Tissue substitute materials and methods for tissue repair |
EP3246050A1 (de) * | 2016-05-17 | 2017-11-22 | BSN medical GmbH | Wund- oder hautauflage |
CN106039425B (zh) * | 2016-07-21 | 2019-02-26 | 四川兴泰普乐医疗科技有限公司 | 用于血管疾病治疗的全降解血管支架及其制备方法 |
US20180133162A1 (en) * | 2016-11-11 | 2018-05-17 | Xiao Yu Wu | Tunable polymeric composite coating for controlled release |
IT201700009221A1 (it) * | 2017-01-27 | 2018-07-27 | Fondazione St Italiano Tecnologia | Procedimento per la sintesi di nanoparticelle magnetiche stimolo-responsive. |
CN107569716B (zh) * | 2017-04-26 | 2020-10-20 | 温州医科大学附属口腔医院 | 一种钛种植体表面pH响应药物控释涂层的制备方法 |
CN107320224B (zh) * | 2017-06-09 | 2019-06-04 | 东华大学 | 纺织基增强型可降解管腔支架及其制备和应用 |
CN108066048B (zh) * | 2017-12-20 | 2019-09-27 | 东华大学 | 热粘合复合结构可降解管腔支架及其制备方法和应用 |
KR102146704B1 (ko) * | 2018-04-13 | 2020-08-21 | 가천대학교 산학협력단 | 사이클로스포린 A (CsA) 경피 및 피내 약물전달용 마이크로구조체 |
CN109701083A (zh) | 2019-01-25 | 2019-05-03 | 上海交通大学医学院附属第九人民医院 | 一种利用生物三维打印和静电纺丝技术制备人工肌腱方法 |
CN110433339B (zh) * | 2019-08-21 | 2021-09-21 | 华南理工大学 | 一种pH响应型原位控释钛基植入体及其制备方法与应用 |
CN112043875B (zh) * | 2020-08-06 | 2022-05-31 | 苏州大学 | 一种原位内膜再生的血管支架覆膜及其制备方法 |
CN113018518B (zh) | 2021-03-05 | 2022-06-03 | 上海交通大学医学院附属新华医院 | 一种用于婴幼儿狭窄血管可吸收血管支架涂层的制备方法 |
-
2021
- 2021-03-05 CN CN202110246916.5A patent/CN113018518B/zh active Active
-
2022
- 2022-03-29 US US18/280,275 patent/US11986575B2/en active Active
- 2022-03-29 WO PCT/CN2022/083531 patent/WO2022184183A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN202069770U (zh) * | 2011-05-19 | 2011-12-14 | 中南大学 | 空白药物载体贴膜 |
CN112043878A (zh) * | 2020-08-06 | 2020-12-08 | 苏州大学 | 一种抗凝血管支架覆膜及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US20240042109A1 (en) | 2024-02-08 |
US11986575B2 (en) | 2024-05-21 |
CN113018518A (zh) | 2021-06-25 |
WO2022184183A1 (zh) | 2022-09-09 |
WO2022184183A9 (zh) | 2023-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tamada et al. | The development of polyanhydrides for drug delivery applications | |
JP3134935B2 (ja) | 分岐ポリアンヒドリド | |
US20060018948A1 (en) | Biodegradable implantable medical devices, methods and systems | |
AU2005205409B2 (en) | Boigradable multi-block co-polymers | |
CA2490007C (en) | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from | |
AU2003268841B2 (en) | Composition and medical devices utilizing bioabsorbable polymeric waxes | |
CA2391898C (en) | Compositions and medical devices utilizing bioabsorbable polymeric waxes | |
JP2008529597A (ja) | ファイバー強化複合材吸収性尿管内ステント | |
US5240963A (en) | Branched polyanhydrides | |
CN102892442B (zh) | 降解速率可调的聚(l-丙交酯)支架的制造方法 | |
WO1997019973A1 (fr) | Nouveaux hydrogels a base de copolymeres trisequences, leur preparation et leur application | |
US20080057128A1 (en) | Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from | |
WO1995003356A1 (en) | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers | |
CN101631518A (zh) | 临时性管腔内支架及其制备和使用方法 | |
KR20040002749A (ko) | 서방출을 위한 중합체 피복된 미세입자 | |
CN113018518B (zh) | 一种用于婴幼儿狭窄血管可吸收血管支架涂层的制备方法 | |
CN101787120B (zh) | 三嵌段聚氨基酸及其水凝胶 | |
US9422396B2 (en) | Biodegradable elastomers prepared by the condensation of an organic di-, tri- or tetra-carboxylic acid and an organic diol | |
CN107427611A (zh) | 药物洗脱泡沫及其生产 | |
CN111840569A (zh) | 一种pH响应性载药纳米粒子 | |
Clelikkaya et al. | Rifampicin Carrying Poly (D, L‐Lactide)/Poly (Ethylene Glycol) Microspheres: Loading and Release | |
KR101242392B1 (ko) | 탄성력과 생분해 기간이 조절되는 블록 공중합체를 포함하는 심혈관 이식구조체 | |
CN116059504A (zh) | 一种用于动静脉瘘狭窄的药物球囊及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |